Biotherapy | Volume, presentation | Effective date of the new retail price | Retail price (excl. VAT, in €) | Reduction in retail price between 2012 and 2015 (percent decrease) |
---|---|---|---|---|
Adalimumab (Humira) | 40 mg syringe or pen | 513.45 | ||
15 Sep 2010 | 462.11 | |||
1 Feb 2013 | 443.62 | |||
1 Aug 2013 | 417.01 | −9.76% | ||
Etanercept (Enbrel) | 25 mg syringe | 126.08 | ||
15 Sep 2010 | 113.47 | |||
24 Apr 2013 | 109.50 | |||
1 Mar 2014 | 105.67 | −6.88% | ||
50 mg syringe or pen | 252.16 | |||
15 Sep 2010 | 226.95 | |||
24 Apr 2013 | 219.00 | |||
1 Mar 2014 | 211.34 | −6.88% | ||
Originator infliximab (Remicade) | 100 mg vial | 561.00 | ||
1 Sep 2009 | 536.28 | |||
1 Oct 2010 | 509.47 | |||
1 Jun 2011 | 482.67 | |||
1 Nov 2014 | 434.40 | −10.0% | ||
Biosimilar infliximab (Inflectra) | 100 mg vial | 27 Jan 2015 | 434.40 |
excl. VAT, exclusive of value added tax.